Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 501–600 of 1,000
Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque
Espinoza, D. A., Fan, X., Yang, D., Cordes, S. F., Truitt, L. L., Calvo, K. R., Yabe, I. M., Demirci, S., Hope, K. J., Hong, S. G., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.003 · Cited by 46
“Evidence implicated RVs activating nearby cellular proto-oncogenes with strong viral enhancers, exacerbated by RV integration favoring transcription start sites (TSSs).(13) LVs had endogenous enhancers removed and were shown to have an integration pattern favoring gene bodies rather than promoters, hypothesized to be…”
BackgroundSelf-citationNishijima, K., & Iijima, S. (2012) · Development Growth & Differentiation · doi:10.1111/dgd.12032 · Cited by 46
“The selection of integration sites for the retrovirus is random, although some preferences are virus-specific (Wu et al. 2003; Mitchell et al. 2004; Lewinski et al. 2006).”
BackgroundA 21st Century View of Evolution
Shapiro, J. A. (2002) · Journal of Biological Physics · doi:10.1023/a:1021207310080 · Cited by 44
Arhel, N. J., Souquère, S., & Charneau, P. (2006) · Retrovirology · doi:10.1186/1742-4690-3-38 · Cited by 45
“In the case of Flap+ vector genomes, hybridization signals were detected predominantly within the open regions of the chromatin, confirming previous work showing preferential integration of HIV-1 within actively transcribed genes [26-28].”
Position‐effect variegation revisited: HUSHing up heterochromatin in human cells
Timms, R. T., Tchasovnikarova, I. A., & Lehner, P. J. (2016) · BioEssays · doi:10.1002/bies.201500184 · Cited by 42
“The integration preferences of human immunodeficiency virus type 1 (HIV-1) [78–81] and other retroviruses [82, 83] are well-studied and, although there is a strong bias towards integration into active transcriptional units, a significant minority of integrations occur in heterochromatin.”
BackgroundCasabianca, A., Gori, C., Orlandi, C., Forbici, F., Perno, C. F., & Magnani, M. (2007) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2007.05.005 · Cited by 40
Trono, D. (2003) · Science · doi:10.1126/science.1086238 · Cited by 46
Gene Therapy of Storage Disorders by Retroviral and Lentiviral Vectors
Biffi, A., & Naldini, L. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1133 · Cited by 45
“In addition, RVs and LVs have been shown to have a strong bias for integration in the proximity of expressed genes, thus making transcriptional interference between the vector and flanking endogenous genes more likely (Schroder et al ., 2002; Wu et al ., 2003; De Palma et al ., 2005).”
Genetic therapies for cystic fibrosis lung disease
Sinn, P. L., Anthony, R. M., & McCray, P. B. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr104 · Cited by 42
Lim, K., Klimczak, R. R., Yu, J. H., & Schaffer, D. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001402107 · Cited by 40
“Consistent with prior reports (5), MLV vector with wild-type Gag-Pol exhibited a strong preference in the human embryonic kidney 293 cell genome for TSS and CpG islands that are known to be enriched in promoters (27) (P 1⁄4 1.”
BackgroundMethodHematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 44
Transfer of human artificial chromosome vectors into stem cells
Oshimura, M., & Katoh, M. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60557-3 · Cited by 42
Development of Gene Therapy for Thalassemia
Nienhuis, A. W., & Persons, D. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011833 · Cited by 38
“Although gammaretroviral vectors have a predilection to integrate near transcriptional start sites (Wu et al. 2003), HIV-based lentiviral vector genomes are more uniformly distributed throughout transcribed genes (Schröder et al. 2002).”
BackgroundEdgecombe, G. D., & David, L. (2013) · Springer eBooks · doi:10.1007/978-3-642-36160-9_15 · Cited by 41
High-Throughput Genomic Mapping of Vector Integration Sites in Gene Therapy Studies
Beard, B. C., Adair, J. E., Trobridge, G. D., & Kiem, H. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1133-2_22 · Cited by 38
Recent Advances in the Biology, Therapy and Management of Melanoma
Davids, L. M. (2013) · InTech eBooks · doi:10.5772/46052 · Cited by 38
Brendel, C., Rothe, M., Santilli, G., Charrier, S., Stein, S., Kunkel, H., Abriss, D., Müller-Kuller, U., Gaspar, H. B., Modlich, U., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.245 · Cited by 40
“21 Significantly more integration sites were found listed in the retroviral tagged cancer gene database (RTCGD) for RV.SF than for both lentiviral vectors (Supplementary Table S5).”
Retroviruses integrate into a shared, non-palindromic DNA motif
Kirk, P., Huvet, M., Melamed, A., Maertens, G. N., & Bangham, C. R. M. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.212 · Cited by 38
Development of CAR-T cell therapy for B-ALL using a point-of-care approach
Abdo, L. D. M., Barros, L. R. C., Viegas, M. S., Marques, L. V. C., Ferreira, P. D. S., Chicaybam, L., & Bonamino, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1752592 · Cited by 40
Gene therapy in combination with tissue engineering to treat epidermolysis bullosa
Ferrari, S., Pellegrini, G., Matsui, T., Mavilio, F., & De Luca, M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.4.367 · Cited by 37
“In fact, whereas retroviruses integrate preferentially near the start site of transcriptional units (either upstream or downstream), an event that has been shown to lead to the activation of protooncogenes, lentiviruses prefer integration anywhere in the transcriptional unit [70-72].”
BackgroundStem cell gene transfer—efficacy and safety in large animal studies
Horn, P. A., Morris, J. C., Neff, T., & Kiem, H. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.017 · Cited by 38
Capsid–host interactions for HIV-1 ingress
Jang, S., & Engelman, A. (2023) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00048-22 · Cited by 42
“Under baseline infection conditions, HIV-1 integration favors gene mid-regions (244).”
BackgroundUchida, N., Washington, K. N., Lap, C. J. G., Hsieh, M. M., & Tisdale, J. F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.218 · Cited by 41
Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 41
Hu, J., Renaud, G., Golmes, T., Ferris, A., Hendrie, P. C., Donahue, R. E., Hughes, S. H., Wolfsberg, T. G., Russell, D. W., & Dunbar, C. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.135 · Cited by 36
Pajer, P., Pečenka, V., Králová, J., Karafiát, V., Průková, D., Zemanová, Z., Kodet, R., & Dvořák, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1728 · Cited by 37
“It is important to mention that some common VIS could arise due to chance (6) or as a result of preferential integration into some genomic regions—preferences for transcriptionally active loci (22) and GC-rich DNA regions (23) have been reported.”
BackgroundHopping around the Tumor Genome: Transposons for Cancer Gene Discovery
Collier, L. S., & Largaespada, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3085 · Cited by 37
“to mutate tumor suppressor genes because they prefer to insert near the 5V end of genes (11).”
BackgroundToward Combined Cell and Gene Therapy for Genodermatoses
Rosa, L. D., Latella, M. C., Seconetti, A. S., Cattelani, C., Bauer, J. W., Bondanza, S., & Luca, M. D. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035667 · Cited by 38
The Herefordshire Lagerstätte: fleshing out Silurian marine life
Siveter, D. J., Briggs, D. E. G., Siveter, D. J., & Sutton, M. D. (2019) · Journal of the Geological Society · doi:10.1144/jgs2019-110 · Cited by 37
Spatial and Genomic Correlates of HIV-1 Integration Site Targeting
Singh, P. K., Bedwell, G. J., & Engelman, A. (2022) · Cells · doi:10.3390/cells11040655 · Cited by 37
“Genic HIV-1 integration under baseline infection conditions preferentially occurs in the mid-regions of gene bodies [6,21,53].”
BackgroundQuivy, V., de Walque, S., & Lint, C. M. V. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5466-1_17 · Cited by 41
Uchida, N., Hargrove, P. W., Lap, C. J., Evans, M. E., Phang, O., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Nguyen, A.-D., Hsieh, M. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.159 · Cited by 36
Gfi1.1 regulates hematopoietic lineage differentiation during zebrafish embryogenesis
Wei, W., Wen, L., Huang, P., Zhang, Z., Chen, Y., Xiao, A., Huang, H., Zhu, Z., Zhang, B., & Lin, S. (2008) · Cell Research · doi:10.1038/cr.2008.60 · Cited by 37
Evaluation of Gene Promoters for Liver Expression by Hydrodynamic Gene Transfer
Nguyen, A. T., Dow, A. C., Kupiec‐Weglinski, J. W., Busuttil, R. W., & Lipshutz, G. S. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2008.02.016 · Cited by 44
“preference for actively transcribing genes [1] making them potentially mutagenic.”
BackgroundSuccesses and risks of gene therapy in primary immunodeficiencies
Chinen, J., & Puck, J. M. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.01.765 · Cited by 38
Aiyer, S., Swapna, G. V. T., Ma, L.-C., Liu, G., Hao, J., Chalmers, G., Jacobs, B. C., Montelione, G. T., & Roth, M. J. (2021) · Structure · doi:10.1016/j.str.2021.01.010 · Cited by 35
Current progress on gene therapy for primary immunodeficiencies
Zhang, L., Thrasher, A. J., & Gaspar, H. B. (2013) · Gene Therapy · doi:10.1038/gt.2013.21 · Cited by 40
Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy
Suerth, J. D., Labenski, V., & Schambach, A. (2014) · Viruses · doi:10.3390/v6124811 · Cited by 39
“While gammaretroviral vectors preferentially integrate in the proximity of transcription start sites, CpG islands, and genes with implications in cancer, lentiviral vectors tend to integrate within transcription units of actively transcribed genes [27,31–41].”
BackgroundRyan, C. P., Brownlie, J. C., & Whyard, S. (2016) · Genome Biology and Evolution · doi:10.1093/gbe/evw284 · Cited by 35
Gene transfer to the outflow tract
Dang, Y., Loewen, R. T., Parikh, H., Roy, P., & Loewen, N. A. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.04.023 · Cited by 36
“MLV appears to favor integration in close proximity to transcription start sites, whichmay be oncogenic if this occurs near a proto-oncogene or disrupts a tumor suppressor gene (Wu et al., 2003).”
BackgroundKim, H. S., Hwang, G., Lee, H. K., Bae, T., Park, S.-H., Kim, Y. J., Lee, S., Park, J.-H., Bae, S., & Hur, J. K. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.012 · Cited by 37
“12 Second, different genomic loci manifest diverse distribution of protein expression capacities, the expression levels of the inserted transgenes can differ from those of endogenous genes, and vary depending on the integration site.”
Sauvageau, M., Miller, M., Lemieux, S., Lessard, J., Hébert, J., & Sauvageau, G. (2008) · Blood · doi:10.1182/blood-2007-07-098236 · Cited by 35
Control of Self‐Renewal and Differentiation of Hematopoietic Stem Cells: HOXB4 on the Threshold
Klump, H., Schiedlmeier, B., & Baum, C. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1349.002 · Cited by 45
The Human β-Globin Locus Control Region Can Silence as Well as Activate Gene Expression
Feng, Y., Warin, R., Li, T., Olivier, E. N., Besse, A., Lobell, A., Fu, H., Lin, C. M., Aladjem, M. I., & Bouhassira, E. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.10.3864-3874.2005 · Cited by 35
“While this model explains silencing at some sites of integration, it does not appear to be true in general for mammalian cells, since transgenes inserted into pericentromeric heterochromatin are sometimes expressed at high levels (25, 35), since the same transgene inserted at the same position can be expressed in one…”
BackgroundHematopoietic Stem Cell Transduction and Amplification in Large Animal Models
Trobridge, G. D., Beard, B. C., & Kiem, H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1355 · Cited by 37
“Another potential disadvantage of gammaretroviral vectors is that they have a strong preference for integration near transcript start sites (Wu et al ., 2003), which may lead to increased risk of malignancy as observed in the French X-linked SCID trial.”
Naughtin, M., Haftek-Terreau, Z., Xavier, J., Meyer, S., Silvain, M., Jaszczyszyn, Y., Levy, N., Miele, V., Benleulmi, M. S., Ruff, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129427 · Cited by 37
“At a given assembly ratio (for example 0.74 μg histone for 1 μg DNA), a higher average number of nucleosomes was obtained for some DNA sequences compared to others (3.03 for DX598014 compared to 2.44 for CL529183, S1 Fig panel C), indicating that some sequences are more favourable for nucleosome assembly.”
BackgroundInfluentialEfficient site-specific transgenesis and enhancer activity tests in medaka using PhiC31 integrase
Kirchmaier, S., Höckendorf, B., Möller, E. K., Bornhorst, D., Spitz, F., & Wittbrodt, J. (2013) · Development · doi:10.1242/dev.096081 · Cited by 35
“We genotyped single fish via fin-clip PCR to identify insertion site and copy number (Grabher and Wittbrodt, 2007) after the third outcross generation.”
MethodInfluentialGene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point of View
Cavazzana, M., Ribeil, J., Lagresle‐Peyrou, C., & André‐Schmutz, I. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0230 · Cited by 37
“In fact, the g-retrovirus’s integration sites were concentrated near the 5¢ ends of transcription units [5], which facilitated the activation of the nearest oncogenes.”
BackgroundMature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1
Heinrich, T., Rengstl, B., Muik, A., Petkova, M. V., Schmid, F., Wistinghausen, R., Warner, K., Crispatzu, G., Hansmann, M., Herling, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.67 · Cited by 37
Johnston, J. M., Denning, G., Doering, C. B., & Spencer, H. T. (2012) · Gene Therapy · doi:10.1038/gt.2012.76 · Cited by 34
Eyles, J. E., Vessillier, S., Jones, A., Stacey, G., Schneider, C. K., & Price, J. (2018) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.5829 · Cited by 34
Bacteriophage Mu integration in yeast and mammalian genomes
Paatero, A., Turakainen, H., Happonen, L., Olsson, C., Palomäki, T., Pajunen, M. I., Meng, X., Otonkoski, T., Tuuri, T., Berry, C. C., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn801 · Cited by 44
Transposon-Mediated Mutagenesis in Somatic Cells
Largaespada, D. A., & Collier, L. S. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-232-8_7 · Cited by 34
Promoter Choice for Retroviral Vectors: Transcriptional Strength Versus Trans-Activation Potential
Weber, E. L., & Cannon, P. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.067 · Cited by 38
“However, the semirandom nature of retroviral integration, with a preference for actively transcribing genes (Wu et al ., 2003), means that retroviral integration events may also be mutagenic.”
Gene therapy approaches for epidermolysis bullosa
Ferrari, S., Pellegrini, G., Mavilio, F., & Luca, M. D. (2005) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.07.017 · Cited by 34
Black, A., Vasireddy, V., Chung, D. C., Maguire, A. M., Gaddameedi, R., Tolmachova, T., Seabra, M., & Bennett, J. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2768 · Cited by 32
“Later studies show that MLV vectors have an integration target site preference for the transcriptional start regions of genes (42-43).”
BackgroundKaufmann, K. B., Brendel, C., Suerth, J. D., Müller-Kuller, U., Chen-Wichmann, L., Schwäble, J., Pahujani, S., Kunkel, H., Schambach, A., Baum, C., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.249 · Cited by 36
Retroviral Insertion Site Analysis in Dominant Haematopoietic Clones
Kustikova, O. S., Modlich, U., & Fehse, B. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-409-4_25 · Cited by 37
Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry
Borrenberghs, D., Dirix, L., Wit, F. D., Rocha, S., Blokken, J., Houwer, S. D., Gijsbers, R., Christ, F., Hofkens, J., Hendrix, J., et al. (2016) · Scientific Reports · doi:10.1038/srep36485 · Cited by 38
Sites of retroviral DNA integration: From basic research to clinical applications
Serrao, E., & Engelman, A. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1102859 · Cited by 36
“…of the human, mouse and other host-genome reference sequences, this marriage of library construction and DNA sequencing led to a wealth of insights into the integration site distribution patterns of different types of retroviruses (Mitchell et al., 2004; Schroder et al., 2002; Wu et al., 2003).”
BackgroundMethodInfluentialHawley, R. G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.142 · Cited by 33
Gene therapy bio-safety: scientific and regulatory issues
Gonin, P., Buchholz, C. J., Pallardy, M. J., & Mezzina, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302629 · Cited by 33
Human Artificial Chromosome Vectors Meet Stem Cells: New Prospects for Gene Delivery
Ren, X., Tahimic, C. G. T., Katoh, M., Kurimasa, A., Inoue, T., & Oshimura, M. (2006) · Stem Cell Reviews and Reports · doi:10.1007/s12015-006-0008-9 · Cited by 35
Rival‐Gervier, S., Lo, M., Khattak, S., Pasceri, P., Lorincz, M. C., & Ellis, J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.131 · Cited by 36
Integration of retroviral vectors
Gabriel, R., Schmidt, M., & Kalle, C. V. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.006 · Cited by 39
“However, on the genome level host factors are thought to confer target site selection and interactions of the viral IN with cellular proteins (see below) as well as influence of transcriptional activity [23,31] and chromatin status [32] are likely further decisive.”
BackgroundBruce, J. W., Ahlquist, P., & Young, J. A. T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000207 · Cited by 36
Therapeutic Potential of siRNA-Mediated Transcriptional Gene Silencing
Morris, K. V. (2006) · BioTechniques · doi:10.2144/000112166 · Cited by 37
Kalle, C. V., Fehse, B., Layh‐Schmitt, G., Schmidt, M., Kelly, P. F., & Baum, C. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.007 · Cited by 36
CTF/NF1 transcription factors act as potent genetic insulators for integrating gene transfer vectors
Gaussin, A., Modlich, U., Bauche, C., Niederländer, N. J., Schambach, A., Duros, C., Artus, A., Baum, C., Cohen‐Haguenauer, O., & Mermod, N. (2011) · Gene Therapy · doi:10.1038/gt.2011.70 · Cited by 34
Thumann, G., Harmening, N., Prat-Souteyrand, C., Marie, C., Pastor, M., Sebe, A., Miskey, C., Hurst, L. D., Diarra, S., Kropp, M., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.002 · Cited by 33
MuLV IN mutants responsive to HDAC inhibitors enhance transcription from unintegrated retroviral DNA
Schneider, W. M., Wu, D.-T., Amin, V., Aiyer, S., & Roth, M. J. (2012) · Virology · doi:10.1016/j.virol.2012.01.034 · Cited by 33
“…by IN K376R indicated the global target site preference with respect to transcriptional start sites and CpG island did not differ significantly from that published in WT MuLV (Wu et al., 2003), eliminating chromosomal positional effects as the cause for decreased gene expression (data not shown).”
BackgroundGenetically engineered immune privileged Sertoli cells: A new road to cell based gene therapy
Kaur, G., Long, C. R., & Dufour, J. M. (2012) · Spermatogenesis · doi:10.4161/spmg.19119 · Cited by 33
“This is a cause for concern since insertion of the gamma-retrovirus is not random but more likely to integrate into transcriptionally active regions of the chromatin.(69,70) No case of insertional mutagenesis has been reported in ADA-SCID trials [another form of SCID, caused by the lack of adenosine deaminase (ADA) en…”
BackgroundComputational identification of insertional mutagenesis targets for cancer gene discovery
de Jong, J., de Ridder, J., van der Weyden, L., Sun, N., van Uitert, M., Berns, A. J. M., van Lohuizen, M., Jonkers, J., Adams, D. J., & Wessels, L. F. A. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr447 · Cited by 33
“The insertion density across all aligned genes is plotted in black below the expression values, and demonstrates an explicit preference of MuLV insertions for loci near the gene start site, as previously observed (14).”
Kim, H. H., van den Heuvel, A. P. J., Schmidt, J. W., & Ross, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027425 · Cited by 32
“A number of groups have used high throughput analysis to identify retroviral integration sites in murine leukemia virus (MLV)-transduced cells and after MLV and MMTV proviral, as well as retrotransposon insertion in tumors as a means of identifying novel oncogenes [2,4,8,9,10,11,12].”
BackgroundGene therapy for childhood immunological diseases
Kohn, D. B. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705895 · Cited by 35
Staal, F. J. T., Pike‐Overzet, K., Ng, Y. Y., & van Dongen, J. J. M. (2008) · Leukemia · doi:10.1038/leu.2008.219 · Cited by 37
“Nevertheless, the lower propensity of lentiviral vectors for integration at the 5′ start side of genes may suggest a preferred safety profile for gene therapy applications of such vectors”
Goffinet, C., Michel, N., Allespach, I., Tervo, H.-M., Hermann, V., Kräusslich, H., Greene, W. C., & Keppler, O. T. (2007) · Retrovirology · doi:10.1186/1742-4690-4-53 · Cited by 39
“Whereas HIV-1 preferentially integrates within active transcription units [40], MLV favours integration at transcription start regions [41,42].”
BackgroundMicroRNAs: key players of normal and malignant myelopoiesis
Alemdehy, M. F., & Erkeland, S. J. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328353d4e9 · Cited by 35
“In addition, the genes that are deregulated because of viral insertional mutagenesis, which is largely dependent on the characteristics of the viral microRNA expression system used, collaborate in oncogenic transformation and may play a role in the different leukemia phenotypes observed [51,52].”
BackgroundUsing retroviruses as a mutagenesis tool to explore the zebrafish genome
Jao, L.-E., Maddison, L. A., Chen, W., & Burgess, S. M. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln038 · Cited by 31
“This apparent preference for MLV to integrate at the 50 end of the gene has also been observed in the mouse [27, 28] and human tissue culture cells [29].”
BackgroundSelf-citationGenotypic Features of Lentivirus Transgenic Mice
Sauvain, M.-O., Dorr, A. P., Stevenson, B. J., Quazzola, A., Naef, F., Wiznerowicz, M., Schütz, F., Jongeneel, C. V., Duboule, D., Spitz, F., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00623-08 · Cited by 31
“Large-scale analyses of retroviral integration sites in somatic cells have revealed that, while vectors derived from both murine leukemia virus (MLV) and HIV favor active genes, the former tend to integrate in and around promoters, whereas the latter rather target transcribed regions (14, 19, 30).”
BackgroundStrauss, B. E., & Costanzi-Strauss, E. (2007) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006005000085 · Cited by 33
“Genomic-style strategies to identify insertion sites and their proximity to candidate genes and regulatory elements (27,28) have shown that MLV retroviruses, such as that used in the X-SCID trial, tend to insert near the promoter region of genes (28).”
BackgroundPodetz-Pedersen, K. M., Bell, J. B., Steele, T. W. J., Wilber, A. C., Shier, W. T., Belur, L. R., McIvor, R. S., & Hackett, P. B. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.128 · Cited by 31
“…chances of causing adverse effects as a result of activation of oncogenes or their regulators (Schroder et al. , 2002; Nakai et al. , 2003; Wu et al. , 2003; Laufs et al. , 2004; Mitchell et al. , 2004; Bushman et al. , 2005; De Palma et al. , 2005; Ciuffi et al. , 2006; Donsante et al. ,…”
Braun, C. J., Witzel, M., Paruzynski, A., Boztuǧ, K., Kalle, C. V., Schmidt, M., & Klein, C. (2014) · Rare Diseases · doi:10.4161/21675511.2014.947749 · Cited by 36
“In contrast to gammaretroviral vectors, lentiviral vectors are characterized by their ability to transduce non-dividing (stem) cells and a genomic integration pattern that does not favor the promoterregion of genes as much as gammaretroviruses do.(30) However, choosing the right internal promoter can be difficult.”
BackgroundCornils, K., Lange, C., Schambach, A., Brugman, M. H., Nowak, R., Lioznov, M. V., Baum, C., & Fehse, B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.238 · Cited by 31
Lentiviral integration preferences in transgenic mice
Yang, S., Cheng, P., Sullivan, R. T., Thomas, J. W., & Chan, A. W. S. (2008) · genesis · doi:10.1002/dvg.20435 · Cited by 35
“Furthermore, FV, MLV, and AAV preferred to integrate within 1 kb of the CpG islands (Trobridge et al ., 2006), which were differed from lentiviral vectors and HIV.”
BackgroundInfluentialGlimm, H. (2005) · Blood · doi:10.1182/blood-2004-07-2859 · Cited by 31
Real-Time Definition of Non-Randomness in the Distribution of Genomic Events
Abel, U., Deichmann, A., Bartholomae, C., Schwarzwaelder, K., Glimm, H., Howe, S., Thrasher, A., Garrigue, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000570 · Cited by 31
“In the case of our clinical example (unpublished data), it is known that retroviral vectors based on the murine leukaemia virus (MLV) tend to integrate into gene coding regions preferentially near the transcriptional start site (TSS) [34-36].”
BackgroundBosticardo, M., Ghosh, A., Du, Y., Jenkins, N. A., Copeland, N. G., & Candotti, F. (2009) · Molecular Therapy · doi:10.1038/mt.2009.172 · Cited by 31
Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia
Müller, L. U. W., & Williams, D. A. (2009) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2009.03.010 · Cited by 31
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
BackgroundThe genomic risk of somatic gene therapy
Kustikova, O. S., Brugman, M. H., & Baum, C. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.06.003 · Cited by 35
Gene and cell therapy based treatment strategies for inflammatory bowel diseases
van der Marel, S., Majowicz, A., van Deventer, S., Petry, H., Hommes, D. W., & Ferreira, V. (2011) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v2.i6.114 · Cited by 31
Genetic engineering with T cell receptors
Zhang, L., & Morgan, R. A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.009 · Cited by 30
“andmay be less prone to insertional mutagenesis due to their random integration unlike gamma-retroviral vectors that have preferential integration near the transcription start sites of genes [32].”
Site-specific Gene Insertion Mediated by a Cre-loxP-carrying Lentiviral Vector
Michel, G., Yu, Y., Chang, T., & Yee, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.150 · Cited by 33
Matrix attachment regions as targets for retroviral integration
Johnson, C., & Levy, L. S. (2005) · Virology Journal · doi:10.1186/1743-422x-2-68 · Cited by 30
“Previous studies have reported that HIV-1, MLV, ASV and HTLV-1 prefer to integrate into genes [11,12,19,20].”
BackgroundInfluentialRetroviral Insertional Mutagenesis Can Contribute to Immortalization of Mature T Lymphocytes
Newrzela, S., Cornils, K., Heinrich, T., Schläger, J., Yi, J.-H., Lysenko, O., Kimpel, J., Fehse, B., & von Laer, D. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00193 · Cited by 29
“Those vectors have the propensity to integrate into active chromatin structures nearby promoter regions (8,9).”
BackgroundKashiwakura, Y., Ohmori, T., Mimuro, J., Yasumoto, A., Ishiwata, A., Sakata, A., Madoiwa, S., Inoue, M., Hasegawa, M., OZAWA, K., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04851.x · Cited by 29
Comparing DNA integration site clusters with scan statistics
Berry, C. C., Ocwieja, K. E., Malani, N., & Bushman, F. D. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu035 · Cited by 27
Siapati, E. K., Bigger, B., Miskin, J., Chipchase, D., Parsley, K. L., Mitrophanous, K. A., Themis, M., Thrasher, A. J., & Bonnet, D. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.022 · Cited by 29
Konstantoulas, C. J., & Indik, S. (2014) · Retrovirology · doi:10.1186/1742-4690-11-34 · Cited by 28
“This property distinguishes MMTV-based vector from other vectors derived from gammaretroviruses and lentiviruses, which preferentially integrate near transcriptional start sites and within genes, respectively [12,13].”
InfluentialChinnasamy, D., Fairbairn, L., Neuenfeldt, J., Treisman, J. S., Hanson, J. P., Margison, G. P., & Chinnasamy, N. (2004) · Human Gene Therapy · doi:10.1089/1043034041648417 · Cited by 29
“…cells (Case et al ., 1999 the start of transcriptional units, whereas human immunodeficiency virus type 1 (HIV-1) preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start (Wu et al ., 2003), implying that these vectors might be less prone to vectors.”
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.